Victoria Socha

DocwireNews

At the National Kidney Foundation Spring Clinical Meetings 2023, Jamie P. Dwyer, MD, and colleagues presented results of a real-world study describing the impact of long-term (&gt;3 months) sodium zirconium cyclosilicate (SZC) therapy on 6-month medical costs in patients with hyperkalemia. The results were presented in a poster titled Medical Costs in Patients With Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: RECOGNIZE II Study.The researchers utilized a large US commercial claims database to retrospectively identify patients &ge;18 years of age who were dispensed SZC (&gt;3-month supply over 6 months) between July 2019 and December 2021. Eligibility criteria were continuous insurance coverage 6 months prior to and 6 months following the index SZC fill.Patients who met inclusion criteria (SZC cohort) were 1:1 exact and propensity-score matched on baseline variables with patients diagnosed with hyperkalemia who did not receive SZC (non-SZC cohort). The primary end point of interest was total hyperkalemia (any diagnosis position) medical costs to payers over 6 months. Secondary end points were hyperkalemia-related medical costs by setting (inpatient, emergency department [ED], outpatient), all-cause medical costs, and all-cause pharmacy costs.The cohorts each included 661 matched patients. Compared with the non-SZC cohort, mean hyperkalemia-related medical costs were reduced by $3728 in the SZC group (P&lt;.001) per patient and all-cause medical costs were reduced by $5492 (P&lt;.01) per patient. Hyperkalemia-related and all-cause inpatient costs were also reduced in the SZC cohort (P&lt;.001 for both). There was an increase in all-cause pharmacy costs in the SZC group of $3621 (P&lt;.01). There were nonsignificant differences in hyperkalemia-related and all-cause ED and outpatient costs.&ldquo;Long-term (&gt;3 months) treatment with SZC was associated with reduced hyperkalemia-related and all-cause medical costs compared with no SZC in patients with hyperkalemia,&rdquo; the researchers said. &ldquo;This suggests potential medical cost saving with long-term SZC therapy in patients with hyperkalemia.&rdquo;Source: Dwyer JP, Agiro A, Desai P, Oluwatosin Y. Medical costs in patients with hyperkalemia on long-term sodium zirconium cyclosilicate therapy: RECOGNIZE II study. (Poster #285). Abstract of a poster presented at the National Kidney Foundation Spring Clinical Meetings 2023; April 11-15, 2023; Austin, Texas. The poster was supported by AstraZeneca.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Medical Costs With SZC Treatment in Hyperkalemia

Hyperkalemia

Results of a study describing the impact of long-term (>3 months) sodium zirconium cyclosilicate therapy on 6-month medical costs in patients with hyperkalemia.

Costs of SCZ therapy in hyperkalemia.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe